Recro Pharma Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Recro Pharma (REPH) Tops Q1 EPS by 96c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
May 10, 2019 7:09 AM EDTRecro Pharma (NASDAQ: REPH) reported Q1 EPS of ($0.10), $0.96 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $25.07 million versus the consensus estimate of $20.51 million.
Our CDMO business is off to a strong start this year, generating $25.1 million in first quarter revenues, a 28% increase from the prior year first quarter, said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. Growth of the Gainesville CDMO continues to accelerate as a result of strong demand... More
